A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use-Reference-Cited by-同舟云学术

A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use

Published:2011-06 Issue: Volume: Page:n/a-n/a
ISSN:0885-6222
Container-title:Human Psychopharmacology: Clinical and Experimental
language:en
Short-container-title:Hum. Psychopharmacol Clin Exp

Author:

Schoedel Kerri Alexandra¹,Chen Nancy¹,Hilliard Annie²,White Linda²,Stott Colin²,Russo Ethan²,Wright Stephen²,Guy Geoffrey²,Romach Myroslava K.¹,Sellers Edward M.¹

Affiliation:

1. Kendle Early Stage-Toronto; Toronto; Ontario; Canada

2. GW Pharma Ltd; Salisbury; UK

Publisher

Wiley

Subject

Pharmacology (medical),Psychiatry and Mental health,Clinical Neurology,Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hup.1196/fullpdf

Reference35 articles.

1. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study;Aragona;Clin Neuropharmacol,2009

2. Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator;Bornheim;Chem Res Toxicol,1998